{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T17:59:14Z","timestamp":1795111154765,"version":"4.10.3"},"reference-count":74,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2021,1,5]],"date-time":"2021-01-05T00:00:00Z","timestamp":1609804800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,2]]},"abstract":"<jats:p>This review summarizes the current evaluation and management of gestational trophoblastic disease, including evacuation of hydatidiform moles, surveillance after evacuation of hydatidiform mole and the diagnosis and management of gestational trophoblastic neoplasia. Most women with gestational trophoblastic disease can be successfully managed with preservation of reproductive function. It is important to manage molar pregnancies properly to minimize acute complications and to identify gestational trophoblastic neoplasia promptly. Current International Federation of Gynecology and Obstetrics guidelines for making the diagnosis and staging of gestational trophoblastic neoplasia allow uniformity for reporting results of treatment. It is important to individualize treatment based on their risk factors, using less toxic therapy for patients with low-risk disease and aggressive multiagent therapy for patients with high-risk disease. Patients with gestational trophoblastic neoplasia should be managed in consultation with an individual experienced in the complex, multimodality treatment of these patients.<\/jats:p>","DOI":"10.1097\/aog.0000000000004240","type":"journal-article","created":{"date-parts":[[2021,1,13]],"date-time":"2021-01-13T19:40:25Z","timestamp":1610566825000},"page":"355-370","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":180,"title":["Gestational Trophoblastic Disease"],"prefix":"10.1097","volume":"137","author":[{"given":"John T.","family":"Soper","sequence":"first","affiliation":[{"name":"Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of North Carolina School of Medicine, Chapel Hill, North Carolina."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,1,5]]},"reference":[{"key":"R1-20260930","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1097\/00003081-200309000-00006","article-title":"Gestational trophoblastic disease epidemiology and trends","volume":"46","author":"Smith","year":"2003","journal-title":"Clin Obstet Gynecol"},{"key":"R2-20260930","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/S1470-2045(03)01245-2","article-title":"Epidemiology and aetiology of gestational trophoblastic diseases","volume":"4","author":"Altieri","year":"2003","journal-title":"Lancet Oncol"},{"key":"R3-20260930","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/ijgo.12615","article-title":"FIGO cancer report 2018. Update on the diagnosis and management of gestational trophoblastic disease","volume":"143","author":"Ngan","year":"2018","journal-title":"Int J Gynecol Obstet"},{"key":"R4-20260930","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/0002-9378(78)90829-3","article-title":"The syndrome of hydatidiform mole. I. Cytogenetics and morphologic correlation","volume":"131","author":"Szulman","year":"1978","journal-title":"Am J Obstet Gynecol"},{"key":"R5-20260930","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/0002-9378(78)90792-5","article-title":"The syndrome of hydatidiform mole. II. Morphologic evaluation of the complete and partial mole","volume":"132","author":"Szulman","year":"1978","journal-title":"Am J Obstet Gynecol"},{"key":"R6-20260930","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1093\/humrep\/15.3.594","article-title":"Repetitive complete hydatidiform mole can be biparental in origin and either male or female","volume":"15","author":"Fisher","year":"2000","journal-title":"Hum Reprod"},{"key":"R7-20260930","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1093\/molehr\/gat056","article-title":"NLRP7 or KhDC3L genes and the etiology of molar pregnancies and recurrent miscarriage","volume":"19","author":"Andreasen","year":"2013","journal-title":"Mol Hum Reprod"},{"key":"R8-20260930","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1007\/s10815-018-1202-9","article-title":"Recurrent complete hydatidiform mole: where are we, is there a safe gestational horizon? Opinion and mini-review","volume":"35","author":"Kalogiannidis","year":"2018","journal-title":"J Assist Reprod Genet"},{"key":"R9-20260930","doi-asserted-by":"crossref","first-page":"270","DOI":"10.4103\/JLP.JLP_130_19","article-title":"Expression of P57 immunomarker in the classification and differential diagnosis of partial and complete hydatidiform moles","volume":"11","author":"Mondal","year":"2019","journal-title":"J Lab Physicians"},{"key":"R10-20260930","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/0029-7844(95)00268-V","article-title":"The changing clinical presentation of complete molar pregnancy","volume":"86","author":"Soto-Wright","year":"1995","journal-title":"Obstet Gynecol"},{"key":"R11-20260930","first-page":"698","article-title":"Complete hydatidiform mole: a disease with a changing profile","volume":"44","author":"Coukos","year":"1999","journal-title":"J Reprod Med"},{"key":"R12-20260930","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.ygyno.2015.05.002","article-title":"Changing presentation of complete hydatidiform mole at the New England Trophoblastic Disease Center over the past three decades: does early diagnosis alter risk for gestational trophoblastic neoplasia?","volume":"138","author":"Sun","year":"2015","journal-title":"Gynecol Oncol"},{"key":"R13-20260930","first-page":"1","article-title":"Hydatidiform mole: diagnosis, management and long-term follow-up of 347 patients","volume":"45","author":"Curry","year":"1975","journal-title":"Obstet Gynecol"},{"key":"R14-20260930","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0002-9378(79)90341-7","article-title":"Acute pulmonary complications of molar pregnancy","volume":"135","author":"Twiggs","year":"1979","journal-title":"Am J Obstet Gynecol"},{"key":"R15-20260930","first-page":"247","article-title":"The natural history of theca lutein cysts","volume":"72","author":"Montz","year":"1988","journal-title":"Obstet Gynecol"},{"key":"R16-20260930","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s12885-018-5168-x","article-title":"Total hysterectomy versus uterine evacuation for preventing post-molar gestational trophoblastic neoplasia in patients who are at least 40 years old: a systematic review and meta-analysis","volume":"19","author":"Zhao","year":"2019","journal-title":"BMC Cancer"},{"key":"R17-20260930","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.ygyno.2017.12.008","article-title":"What is the optimal duration of human chorionic gonadotropin surveillance following evacuation of a molar pregnancy? A retrospective analysis on over 20,000 consecutive patients","volume":"148","author":"Coyle","year":"2018","journal-title":"Gynecol Oncol"},{"key":"R18-20260930","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1097\/AOG.0000000000003566","article-title":"Gestational trophoblastic neoplasia after human chorionic gonadotropin normalization following molar pregnancy. A systematic review and meta-analysis","volume":"135","author":"Albright","year":"2020","journal-title":"Obstet Gynecol"},{"key":"R19-20260930","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.6004\/jnccn.2019.0053","article-title":"Gestational trophoblastic neoplasia, version 2.2019","volume":"17","author":"Abu-Rustum","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"key":"R20-20260930","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1006\/gyno.1999.5468","article-title":"How soon is it safe to undertake pregnancy after trophoblastic tumor?","volume":"94","author":"Kohorn","year":"1999","journal-title":"Gynecol Oncol"},{"key":"R21-20260930","first-page":"588","article-title":"Outcome of pregnancies occurring within 1 year of hydatidiform mole","volume":"94","author":"Tuncer","year":"1999","journal-title":"Obstet Gynecol"},{"key":"R22-20260930","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/0002-9378(89)90295-0","article-title":"Hormonal contraception and trophoblastic sequelae after hydatidiform mole","volume":"160","author":"Curry","year":"1989","journal-title":"Am J Obstet Gynecol"},{"key":"R23-20260930","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.ygyno.2005.09.031","article-title":"Influence of oral contraceptives in the development of post-molar trophoblastic neoplasia \u2013 a systematic review","volume":"100","author":"Costa","year":"2006","journal-title":"Gynecol Oncol"},{"key":"R24-20260930","first-page":"22","article-title":"Risk of recurrent hydatidiform mole and subsequent pregnancy outcome following complete or partial hydatidiform molar pregnancy","volume":"110","author":"Sebire","year":"2003","journal-title":"BJOB"},{"key":"R25-20260930","first-page":"188","article-title":"Subsequent pregnancy outcomes after complete and partial molar pregnancy, recurrent molar pregnancy and gestational trophoblastic neoplasia: an update from the New England Trophoblastic Disease Center","volume":"59","author":"Vargas","year":"2014","journal-title":"J Reprod Med"},{"key":"R27-20260930","first-page":"546","article-title":"Management of twin pregnancies consisting of a complete hydatidiform mole and normal fetus","volume":"91","author":"Fishman","year":"1998","journal-title":"Obstet Gynecol"},{"key":"R28-20260930","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1093\/humrep\/15.3.608","article-title":"Hydatidiform mole coexistent with a twin fetus: a national collaborative study in Japan","volume":"15","author":"Matsui","year":"2000","journal-title":"Hum Reprod"},{"key":"R29-20260930","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1016\/S0140-6736(02)09085-2","article-title":"Outcome of twin pregnancies with complete hydatidiform mole and healthy co-twin","volume":"359","author":"Sebire","year":"2002","journal-title":"Lancet"},{"key":"R30-20260930","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ygyno.2017.01.021","article-title":"Multiple pregnancies with complete mole and coexisting normal fetus in North and South America: a retrospective multicenter cohort and literature review","volume":"145","author":"Lin","year":"2017","journal-title":"Gynecol Oncol"},{"key":"R31-20260930","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0020-7292(03)90120-2","article-title":"FIGO Committee on Gynecologic Oncology. Gestational trophoblastic neoplasia, FIGO 2000 staging and classification","volume":"83","author":"Ngan","year":"2003","journal-title":"Int J Gynecol Obstet"},{"key":"R32-20260930","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1016\/0002-9378(90)90907-O","article-title":"Diagnostic and therapeutic curettage in gestational trophoblastic disease","volume":"162","author":"Schlaerth","year":"1990","journal-title":"Am J Obstet Gynecol"},{"key":"R33-20260930","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ygyno.2005.06.032","article-title":"The curative effect of a second curettage in persistent trophoblastic disease: a retrospective cohort survey","volume":"99","author":"Van Trommel","year":"2005","journal-title":"Gynecol Oncol"},{"key":"R34-20260930","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.ygyno.2004.08.045","article-title":"The role of repeat uterine evacuation in the management of persistent gestational trophoblastic disease","volume":"95","author":"Pezeshki","year":"2004","journal-title":"Gynecol Oncol"},{"key":"R35-20260930","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1097\/AOG.0000000000001554","article-title":"Second curettage for low-risk gestational trophoblastic neoplasia","volume":"128","author":"Osborne","year":"2016","journal-title":"Obstet Gynecol"},{"key":"R36-20260930","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1097\/AOG.0000000000003232","article-title":"Second curettage and number of chemotherapy courses in postmolar gestational trophoblastic neoplasia: a randomized controlled trial","volume":"133","author":"Hemida","year":"2019","journal-title":"Obstet Gynecol"},{"key":"R37-20260930","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ygyno.2005.12.046","article-title":"Gestational trophoblastic diseases: 3. Human chorionic gonadotropin-free B-subunit, a reliable marker of placental site trophoblastic tumors","volume":"102","author":"Cole","year":"2006","journal-title":"Gynecol Oncol"},{"key":"R38-20260930","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1111\/j.1471-0528.1995.tb11429.x","article-title":"Presentation and management of choriocarcinoma after nonmolar pregnancy","volume":"102","author":"Tidy","year":"1995","journal-title":"Br J Obstet Gynaecol"},{"key":"R39-20260930","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1002\/1097-0142(19900401)65:7<1647::AID-CNCR2820650732>3.0.CO;2-9","article-title":"Efficacy of the metastatic screening in the staging of gestational trophoblastic disease","volume":"65","author":"Hunter","year":"1990","journal-title":"Cancer"},{"key":"R40-20260930","first-page":"338","article-title":"Metastatic gestational trophoblastic disease: prognostic factors in previously untreated patients","volume":"71","author":"Soper","year":"1988","journal-title":"Obstet Gynecol"},{"key":"R41-20260930","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1097\/00006250-198609000-00011","article-title":"Role of computed axial tomography of the chest in staging patients with non-metastatic gestational trophoblastic disease","volume":"68","author":"Mutch","year":"1986","journal-title":"Obstet Gynecol"},{"key":"R42-20260930","first-page":"1","article-title":"Gestational trophoblastic disease","volume":"692","year":"1983","journal-title":"WHO Tech Rep Ser"},{"key":"R43-20260930","first-page":"969","article-title":"Evaluation of prognostic factors and staging in gestational trophoblastic tumor","volume":"84","author":"Soper","year":"1994","journal-title":"Obstet Gynecol"},{"key":"R44-20260930","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1046\/j.1525-1438.2000.010004318.x","article-title":"A retrospective comparison of current and proposed staging and scoring systems for persistent gestational trophoblastic disease","volume":"10","author":"Hancock","year":"2000","journal-title":"Int J Gynecol Cancer"},{"key":"R45-20260930","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1586\/14737140.2015.1088786","article-title":"Optimal management of low-risk gestational trophoblastic neoplasia","volume":"15","author":"Goldstein","year":"2015","journal-title":"Expert Rev Anti Cancer Ther"},{"key":"R47-20260930","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1200\/JCO.2010.30.4386","article-title":"Phase III trial of weekly methotrexate or pulsed dactinomycin for low-risk gestational trophoblastic neoplasia: a gynecologic oncology group study","volume":"29","author":"Osborne","year":"2011","journal-title":"J Clin Oncol"},{"key":"R48-20260930","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.ygyno.2017.10.028","article-title":"Effectiveness and toxicity of first-line methotrexate chemotherapy in low-risk postmolar gestational trophoblastic neoplasia: the New England Trophoblastic Disease Center experience","volume":"148","author":"Maest\u00e1","year":"2018","journal-title":"Gynecol Oncol"},{"key":"R49-20260930","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0090-8258(81)90147-5","article-title":"Recurrent gestational trophoblastic disease","volume":"12","author":"Surwit","year":"1981","journal-title":"Gynecol Oncol"},{"key":"R50-20260930","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.ygyno.2012.03.003","article-title":"Relapse rates after two versus three consolidation courses of methotrexate in the treatment of low-risk gestational trophoblastic neoplasia","volume":"125","author":"Lybol","year":"2012","journal-title":"Gynecol Oncol"},{"key":"R51-20260930","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/0002-9378(80)91041-8","article-title":"The role of operation in the current therapy of gestational trophoblastic disease","volume":"136","author":"Hammond","year":"1980","journal-title":"Am J Obstet Gynecol"},{"key":"R52-20260930","first-page":"431","article-title":"Adjuvant hysterectomy in low-risk gestational trophoblastic disease","volume":"97","author":"Suzuka","year":"2001","journal-title":"Obstet Gynecol"},{"key":"R53-20260930","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.ygyno.2018.05.030","article-title":"First-line hysterectomy for women with low-risk non-metastatic gestational trophoblastic neoplasia no longer wishing to conceive","volume":"150","author":"Bolze","year":"2018","journal-title":"Gynecol Oncol"},{"key":"R54-20260930","first-page":"283","article-title":"Actinomycin D for methotrexate-failed low-risk gestational trophoblastic neoplasia","volume":"56","author":"Lurain","year":"2012","journal-title":"J Reprod Med"},{"key":"R55-20260930","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.ygyno.2016.10.001","article-title":"Risk adapted single-agent dactinomycin or carboplatin for second-line treatment of methotrexate resistant low-risk gestational trophoblastic neoplasia","volume":"143","author":"Winter","year":"2016","journal-title":"Gynecol Oncol"},{"key":"R56-20260930","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1097\/IGC.0000000000001248","article-title":"Efficacy and safety of second-line 5-day dactinomycin in case of methotrexate failure for gestational trophoblastic neoplasia","volume":"28","author":"Prouvot","year":"2018","journal-title":"Int J Gynecol Cancer"},{"key":"R57-20260930","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.1997.15.7.2636","article-title":"EMA\/CO for high-risk gestational trophoblastic tumors: results from a cohort of 272 patients","volume":"15","author":"Bower","year":"1997","journal-title":"J Clin Oncol"},{"key":"R58-20260930","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1200\/JCO.2012.43.1817","article-title":"EMA\/CO for high-risk gestational trophoblastic neoplasia: god outcomes with induction low-dose etoposide-cisplatin and genetic analysis","volume":"31","author":"Alifragis","year":"2013","journal-title":"J Clin Oncol"},{"key":"R59-20260930","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.ajog.2015.09.083","article-title":"Mortality rate of gestational trophoblastic neoplasia with a FIGO score of > 13","volume":"214","author":"Bolze","year":"2016","journal-title":"Am J Obstet Gynecol"},{"key":"R60-20260930","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1006\/gyno.1995.0013","article-title":"Gestational trophoblastic disease metastatic to the central nervous system","volume":"59","author":"Evans","year":"1995","journal-title":"Gynecol Oncol"},{"key":"R61-20260930","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.ygyno.2015.01.530","article-title":"Brain metastases in gestational trophoblast neoplasia: an update on incidence, management and outcome","volume":"137","author":"Savage","year":"2015","journal-title":"Gynecol Oncol"},{"key":"R62-20260930","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s10147-018-1337-9","article-title":"Gestational trophoblastic neoplasia with brain metastases at initial presentation: a retrospective study","volume":"24","author":"Gavanier","year":"2019","journal-title":"Int J Clin Oncol"},{"key":"R63-20260930","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/S1521-6934(03)00091-9","article-title":"Role of surgery and radiation therapy in the management of gestational trophoblastic disease","volume":"17","author":"Soper","year":"2003","journal-title":"Best Prac Res Clin Obstet Gynaecol"},{"key":"R65-20260930","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1016\/S0140-6736(17)32894-5","article-title":"Pembrolizumab is effective for drug-resistant gestational trophoblastic neoplasia","volume":"390","author":"Ghorani","year":"2017","journal-title":"Lancet"},{"key":"R66-20260930","doi-asserted-by":"crossref","first-page":"100574","DOI":"10.1016\/j.gore.2020.100574","article-title":"A case of multi-agent drug resistant choriocarcinoma treated with pembrolizumab","volume":"32","author":"Goldfarb","year":"2020","journal-title":"Gynecol Oncol Rep"},{"key":"R67-20260930","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1200\/JCO.20.00803","article-title":"Avelumab in patients with gestational trophoblastic tumors with resistance to single-agent chemotherapy: cohort A of the TROPHIMMUN phase II trial","volume":"38","author":"You","year":"2020","journal-title":"J Clin Oncol"},{"key":"R68-20260930","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1002\/1097-0142(19900901)66:5<978::AID-CNCR2820660529>3.0.CO;2-3","article-title":"Recurrent gestational trophoblastic disease: experience of the southeastern regional trophoblastic disease center","volume":"66","author":"Mutch","year":"1990","journal-title":"Cancer"},{"key":"R69-20260930","first-page":"829","article-title":"Relapsed gestational trophoblastic neoplasia: a 20 year experience","volume":"51","author":"Ngan","year":"2006","journal-title":"J Reprod Med"},{"key":"R70-20260930","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ygyno.2019.07.024","article-title":"When to stop human chorionic gonadotropin (hCG) surveillance after treatment with chemotherapy for gestational trophoblastic neoplasia (GTN): a national analysis on over 4,000 patients","volume":"155","author":"Balachandran","year":"2019","journal-title":"Gynecol Oncol"},{"key":"R71-20260930","first-page":"193","article-title":"Reproductive performance of patients after gestational trophoblastic disease","volume":"22","author":"Loret de Mola","year":"1995","journal-title":"Semin Oncol"},{"key":"R72-20260930","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1006\/gyno.1998.5167","article-title":"Subsequent reproductive experience after treatment for gestational trophoblastic disease","volume":"71","author":"Kim","year":"1998","journal-title":"Gynecol Oncol"},{"key":"R73-20260930","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1111\/j.1471-0528.1998.tb10271.x","article-title":"Influence of chemotherapy for gestational trophoblastic disease on subsequent pregnancy outcome","volume":"103","author":"Woolas","year":"1998","journal-title":"Br J Obstet Gynaecol"},{"key":"R74-20260930","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1200\/JCO.2014.57.5332","article-title":"Effects of single-agent and combination chemotherapy for gestational trophoblastic tumors on risks of second malignancy and early menopause","volume":"33","author":"Savage","year":"2015","journal-title":"J Clin Oncol"},{"key":"R75-20260930","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.ygyno.2016.05.006","article-title":"Placental site trophoblastic tumor: a review of 108 cases and their implications for prognosis and treatment","volume":"142","author":"Zhao","year":"2016","journal-title":"Gynecol Oncol"},{"key":"R76-20260930","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.ygyno.2012.11.010","article-title":"Placental site and epithelioid trophoblastic tumours: diagnostic pitfalls","volume":"128","author":"Moutte","year":"2013","journal-title":"Gynecol Oncol"},{"key":"R77-20260930","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.ygyno.2018.11.015","article-title":"Management and prognostic factors of epithelioid trophoblastic tumors: results from the International Society for the Study of Trophoblastic Diseases database","volume":"152","author":"Frijstein","year":"2019","journal-title":"Gynecol Oncol"}],"container-title":["Obstetrics &amp; Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/AOG.0000000000004240","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T19:00:19Z","timestamp":1790794819000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/AOG.0000000000004240"}},"subtitle":["Current Evaluation and Management"],"short-title":[],"issued":{"date-parts":[[2021,1,5]]},"references-count":74,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/aog.0000000000004240","relation":{},"ISSN":["0029-7844","1873-233X"],"issn-type":[{"value":"0029-7844","type":"print"},{"value":"1873-233X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,5]]},"assertion":[{"value":"2020-09-15","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-10-29","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}